Toggle light / dark theme

As we approach the end of 2020, according to the U.S. National Cancer Institute (NCI), we have had approximately 1, 806, 590 new cases of cancer diagnosed in the United States, with 606, 520 deaths. Cancer continues to be the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide.

By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.

Dr. Azra Raza, MD, is the Chan Soon-Shiong Professor of Medicine, in the Department of Medicine, Division of Hematology / Oncology, and Director of the Myelodysplastic Syndrome (MDS) Center, at the Columbia University Medical Center.

Previously, Dr. Raza was the Chief of Hematology-Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts.

Circa 2002


The potential threat of biological warfare with a specific agent is proportional to the susceptibility of the population to that agent. Preventing disease after exposure to a biological agent is partially a function of the immunity of the exposed individual. The only available countermeasure that can provide immediate immunity against a biological agent is passive antibody. Unlike vaccines, which require time to induce protective immunity and depend on the host’s ability to mount an immune response, passive antibody can theoretically confer protection regardless of the immune status of the host. Passive antibody therapy has substantial advantages over antimicrobial agents and other measures for postexposure prophylaxis, including low toxicity and high specific activity. Specific antibodies are active against the major agents of bioterrorism, including anthrax, smallpox, botulinum toxin, tularemia, and plague. This article proposes a biological defense initiative based on developing, producing, and stockpiling specific antibody reagents that can be used to protect the population against biological warfare threats.

Defense strategies against biological weapons include such measures as enhanced epidemiologic surveillance, vaccination, and use of antimicrobial agents, with the important caveat that the final line of defense is the immune system of the exposed individual. The potential threat of biological warfare and bioterrorism is inversely proportional to the number of immune persons in the targeted population. Thus, biological agents are potential weapons only against populations with a substantial proportion of susceptible persons. For example, smallpox virus would not be considered a useful biological weapon against a population universally immunized with vaccinia.

Vaccination can reduce the susceptibility of a population against specific threats provided that a safe vaccine exists that can induce a protective response. Unfortunately, inducing a protective response by vaccination may take longer than the time between exposure and onset of disease. Moreover, many vaccines require multiple doses to achieve a protective immune response, which would limit their usefulness in an emergency vaccination program to provide rapid prophylaxis after an attack. In fact, not all vaccine recipients mount a protective response, even after receiving the recommended immunization schedule. Persons with impaired immunity are often unable to generate effective response to vaccination, and certain vaccines may be contraindicated for them (1). For example, the vaccine against hepatitis B does not elicit an antibody response in approximately 10% of vaccines, and the percentage of nonresponders is substantially higher in immunocompromised persons (1).

O,.o circa 2018.


Bats’ extraordinary super-immunity long has fascinated virologists.

The U.S. military has a long history of enlisting the help of animals in warfare. The bottlenose dolphin’s sophisticated bio sonar enabled the Navy to detect and clear underwater bombs during the Iraq War, and homing pigeons played a vital role as secret messengers during both world wars, with some awarded medals for bravery.

But there is one animal the military has had significantly less success in conscripting, and that is the bat.

Lately, there has been a flood of interest in gravitational waves. After the first official detection at LIGO / Virgo in 2015, data has been coming in showing how common these once theoretical phenomena actually are. Usually they are caused by unimaginably violent events, such as a merging pair of black holes. Such events also have a tendency to emit another type of phenomena—light. So far, it has been difficult to observe any optical associated with these gravitational-wave emitting events. But a team of researchers hope to change that with the full implementation of the Gravitation-wave Optical Transient Observer (GOTO) telescope.

The GOTO project is designed specifically to find and monitor the parts of the sky that other instruments, such as LIGO, detect from. Its original incarnation, known as the GOTO-4 Prototype, was brought online in 2017. Located in La Palma, in the Canary Islands, this prototype consisted of four “unit telescopes” (UTs) housed in an 18ft clamshell dome. In 2020, this prototype was upgraded to 8 UTs, allowing for a much wider view of the sky.

The wide field of view is necessary for its work detecting gravitational-wave based optical , as directionality of gravitational waves are notoriously difficult to pin down. The wider the field of view of a , the more likely it will be able to detect an event that happens.

Eighty-one years ago, our world-class research center in California’s Silicon Valley was born. Ground broke on Ames Research Center on Dec. 20, 1939. It was the second aeronautical laboratory established by the National Advisory Committee for Aeronautics to perform fundamental research on all things flight. From its very beginnings, Ames was a place for innovation. Tests performed in its wind tunnels transformed military aircraft during World War II and paved the way for air travel at supersonic speeds. In the 1950s and ‘60s, its researchers looked to the stars and came up with new designs and materials for spacecraft that would make human spaceflight a reality. Fast-forward to the present, and the center contributes to virtually every major agency mission through its expertise in spacecraft entry systems, robotics, aeronautics, supercomputing, and so much more! Here are things to know about Ames.

The Volatiles Investigating Polar Exploration Rover is the latest lunar exploration mission led by Ames. Launching in 2023, the mobile robot will search for water ice inside craters and other places at the Moon’s South Pole. Its survey will help pave the way for astronaut missions to the lunar surface beginning in 2024 as part of the Artemis program.

Make sure to follow us on Tumblr for your regular dose of space: http://nasa.tumblr.com/.

Hong Kong scientists claim they have made a potential breakthrough discovery in the fight against infectious diseases—a chemical that could slow the spread of deadly viral illnesses.

A team from the University of Hong Kong described the newly discovered chemical as “highly potent in interrupting the life cycle of diverse viruses” in a study published this month in the journal Nature Communications.

The scientists told AFP Monday that it could one day be used as a broad-spectrum antiviral for a host of —and even for viruses that have yet to emerge—if it passes clinical trials.

Go big or go home. This Alabama-based start-up just unveiled the biggest drone in the world — and it looks sublime. The massive drone, called the Ravn X, is designed to launch small satellites into orbit while airborne.

Aevum — the space startup — has worked mainly in the background, until yesterday when they unveiled their gigantic autonomous drone.

They built the high-altitude aircraft and launch vehicle to ferry satellites to orbit and improve space access — similar goals to space-tech leaders like Virgin Orbit, Rocket Lab, and SpaceX. But if you want to get ahead of the competition and can’t be the first, why not be the biggest?